- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02103686
Study for Comparing The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects
August 28, 2014 updated by: IlDong Pharmaceutical Co Ltd
A Randomized, Open-label, 3-way Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects
The purpose of this study is to:
- Compare the pharmacokinetics profiles of pregabalin sustained release tablet (300mg) to immediate release capsule(150mg * 2).
- Evaluate the effectiveness of food to pharmacokinetics profile of Pregabalin sustained release tablet.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 44 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- 19~44 aged healthy adult.
- someone tho has at least 50kg body weight and ideal body weight ±20%
Exclusion Criteria:
- someone has acute symptom at screening phase
- someone has any disease or symptoms which is clinically significant
- someone had been determined during healthy examination in screening period
- AST or ALT > 1.25 times than normal
- Total bilirubin > 1.5 times than normal
- someone who has a history of allergy, anaphylaxis, drug abuse or misuse.
- someone who had enrolled to other clinical trial within the last 60 days.
- someone who had donated blood within the last 60 days.
- someone who can't take a meal derived from this trial.
- someone who has taken abnormal meals like which can affect to drug ADME
- someone who has taken other ETC drugs or oriental drugs within the last 14 days, Or OTC drugs within the last 7 days
- someone who has taken caffein continuously (coffee or green tea more than 5 cups per a day) or took caffein since 24hours before.
- someone who has taken alcohol more than 30g/day or smoked more than 10 piece of tobacco/day.
- someone who has galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Immediate release capsule
Immediate release capsule treatment under fasted condition
|
|
Experimental: sustained release tablet
sustained release tablet treatment under fasted condition
|
sustained release formulation of pregabalin
|
Experimental: sustained release tablet (high fat meal)
sustained release tablet under high fat meal condition.
|
sustained release formulation of pregabalin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax, AUC of pregabalin
Time Frame: 0~36h
|
0~36h
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety evaluation
Time Frame: 0~24day
|
0~24day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2012
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
January 1, 2013
Study Registration Dates
First Submitted
March 18, 2014
First Submitted That Met QC Criteria
April 1, 2014
First Posted (Estimate)
April 4, 2014
Study Record Updates
Last Update Posted (Estimate)
September 1, 2014
Last Update Submitted That Met QC Criteria
August 28, 2014
Last Verified
September 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Anti-Anxiety Agents
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Pregabalin
Other Study ID Numbers
- ID-PRSD-1201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on High fat meal
-
USDA, Western Human Nutrition Research CenterTerminatedObesity | Overweight | Body WeightUnited States
-
Agroscope Liebefeld-Posieux Research Station ALPCompletedObesity | Nutritional InterventionSwitzerland
-
Pennington Biomedical Research CenterCompletedDiabetes Mellitus, Type 2United States
-
Hospital Universitari Vall d'Hebron Research InstituteCompleted
-
Universidad IcesiUniversidad de San BuenaventuraCompletedCardiovascular DiseasesColombia
-
Wageningen UniversityTop Institute Food and NutritionCompletedCardiovascular Disease | Endothelial DysfunctionNetherlands
-
University of ReadingUnilever R&DCompletedCardiovascular DiseaseUnited Kingdom
-
Boehringer IngelheimCompleted
-
University of Missouri-ColumbiaCompleted
-
Virginia Commonwealth UniversitySigma XiCompletedLipemia | Cardiovascular Risk FactorUnited States